Analyzing Ultragenyx Pharmaceutical (NASDAQ:RARE) & Beyondspring (NASDAQ:BYSI)
Ultragenyx Pharmaceutical (NASDAQ:RARE) and Beyondspring (NASDAQ:BYSI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.
Risk and Volatility
Ultragenyx Pharmaceutical has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Beyondspring has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.
This table compares Ultragenyx Pharmaceutical and Beyondspring’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ultragenyx Pharmaceutical||$51.49 million||45.97||-$197.61 million||($7.39)||-5.54|
Beyondspring has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Beyondspring is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
5.7% of Beyondspring shares are held by institutional investors. 7.8% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Ultragenyx Pharmaceutical and Beyondspring, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ultragenyx Pharmaceutical presently has a consensus target price of $73.36, suggesting a potential upside of 79.07%. Beyondspring has a consensus target price of $41.00, suggesting a potential upside of 174.61%. Given Beyondspring’s higher probable upside, analysts plainly believe Beyondspring is more favorable than Ultragenyx Pharmaceutical.
This table compares Ultragenyx Pharmaceutical and Beyondspring’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Ultragenyx Pharmaceutical beats Beyondspring on 8 of the 13 factors compared between the two stocks.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.